English articles
- Animal Studies Are Not Disappearing. Drug Development Rules Are Changing.
- When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing
- RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived
- Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype
- After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product
- The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class
- Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena
- Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race
- Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job.
- Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy
- Why Has Japan Struggled to Build Global-Scale Biotech Companies?
- GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last
- Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot
- Off-the-Shelf CAR-T in 2026: Rebounding From the Trough
- Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?
- Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition
- RevMed Says No to Being Bought: Biotech's Independent Era
- Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find
- Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology
- GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy
- The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors
- The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer
- Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside
- Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?
- Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet
- Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head
- The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?
- Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer
- Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy
- GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases
